Hundreds of millions of people worldwide suffer from neuropsychiatric and neurodevelopmental disorders that are severe, enduring, and come at a very significant cost. Whereas brain disorders associated with aging, i.e., dementia and Parkinson's disease, are widely recognized as priorities to be urgently addressed by industries, public institutions, and charities, less attention is paid to neurodevelopmental disorders such as autism (autism spectrum disorders [ASDs] ), despite their high prevalence and impact on society. ASDs comprise a family of highly genetic, heterogeneous, neurodevelopmental disorders characterized by deficits in social interaction and communication, and by unusual repetitive behaviors. Around 1% of all children suffer from ASDs, making them more common than childhood cancer, juvenile diabetes, and pediatric AIDS combined. Thus, an estimated three million patients in the European Union (EU), 1.5 million patients in the United States (US), and tens of millions of patients worldwide are affected by ASDs.
As for all neuropsychiatric/neurodevelopmental disorders, we should have made more progress in reducing the disease burden of ASDs. Basic neuroscience is in its ''discovery heyday'' of potential molecular mechanisms underpinning a large number of disorders, and major investments have been made in the EU and the US to understand how the brain works in health and disease (e.g., the Human Brain Project and the NIH Brain Initiative). Yet it is still unclear whether and/or when these large-scale research endeavors will translate into new therapies. We suggest that the challenges and the potential solutions include a complex interaction between knowledge of disease biology together with the way science, industry, and regulators are organized.
Scientific challenges for most neuropsychiatric/neurodevelopmental disorders include disease heterogeneity, biological/clinical overlap between disorders, and absence of reliable disease biomarkers. Most of these disorders also likely have a large number of causative (and disease-modifying) mechanisms that impact a smaller number of final common pathways. Moreover, we will need to modulate pathophysiology in people who have had a brain disorder (or are at ultrahigh risk for developing one) for many years/decades. Hence, besides the complex scientific challenges to be addressed for the identification of molecular mechanisms that may provide therapeutic targets, it is essential to develop innovative tools to assess the efficiency of therapeutic interventions, to delineate the patient populations that will benefit from them, and to intervene at a stage where the brain changes are reversible. Furthermore, lessons learned in other difficult disease areas such as cancer suggest that the most effective therapeutic strategies in ASDs will be based on combinations of treatments that target different aspects of final common pathways over a relatively long time period. This is illustrated by recent evidence that the pathophysiology of ASDs may include a combination of GABAergic and inflammatory mechanisms acting at different developmental time points (Voineagu et al., 2011) .
Basic neuroscience also faces political/ cultural challenges to being more rapidly (and cost-effectively) translated into treatments. Current funding mechanisms understandably mainly support grants that are relatively short term and narrowly focused. Also, many neuroscientists (1) do not work in multidisciplinary groups, (2) are not trained to seek a ''translational'' application for their work by structuring experiments that will lead to treatments that can gain regulatory approval, (3) (incorrectly) assume that if they identify a mechanism it will then be ''picked up'' by industry and developed into a treatment, and/or (4) do not apply the stringent rigor in compound testing as done in industry. Perhaps most importantly the experimental models typically employed by basic scientists (including those in industry) mainly investigate one potential causative mechanism and at one time point. This approach misses the most likely causative and clinical scenarios (interacting causative mechanisms with differing effects across development, and the interaction with other treatments already being prescribed for very commonly associated mental health comorbidities). In other words, how likely is it that a treatment targeting one molecular mechanism, tested in rodents at one developmental time point, and piloted in small groups of medication-free individuals with a clinical disorder, is going to work in ''real-world'' populations of clinically (and biologically) heterogeneous individuals, who typically are of varying ages, already receiving a variety of different medications, and suffering from very common comorbidities (such as intellectual disability, depression, anxiety, or ADHD) that are all associated with biological variation and impact on outcome?
Facing this complexity, the pharmaceutical industry is reluctant to invest in research and development on disorders such as ASDs, and especially to conduct the costly large-scale, long-term clinical trials that are needed to move therapeutic approaches forward. Moreover, this commercial reluctance is reinforced because the key parameters to demonstrate drug efficacy are not established, the regulatory environment is uncertain, and the overall risk of failure is very high. These legitimate concerns should be urgently addressed, since recent important advances have generated new hopes for pharmacological intervention in ASDs. First, promising drug targets have been identified, and perhaps especially the metabotropic glutamate (Williams, 2012) and GABA-A receptors (Han et al., 2014) . Second, there is evidence in a mouse model of ASDs that neuronal alteration can be reversed after completion of brain development (Baudouin et al., 2012) . Third, recent evidence suggests that certain genetic mutations might be used to stratify ASD patients early in development (Bernier et al., 2014) . And fourth, the potential for biomarkers to further aid clinical stratification has emerged from neuroimaging, eye tracking, and electrophysiological studies (including adults; see Ecker et al., 2010) .
In order to take the best advantage of this recent progress, pharmaceutical companies organize collaborative efforts at different levels. Above all, major companies active in the field recognize that neuroscience may prove to be a privileged area for noncompetitive research, and so they will likely benefit from joining forces with each other, and academia, to address some of the most difficult challenges related to ASDs. As an example, by sharing their experience and pooling data from 34 previous trials with antipsychotic agents in schizophrenia, five companies working with academic partners produced evidence that (by focusing on relevant symptoms and paying attention to gender balance) it is possible to significantly reduce both the number of patients and the duration of observation to demonstrate drug efficacy (Rabinowitz et al., 2014) . Collaboration between industry and academia is also expanding beyond the usual bilateral agreement between a single company and a given university. For instance, the building of large public-private consortia is increasingly driven by novel research strategies based on the collection and management of large data sets, the so-called ''big data'' approaches, which might revolutionize research in neurosciences (Manji et al., 2014) .
In ASDs, the consortium EU-AIMS launched by the Innovative Medicines Initiative (IMI) represents the most important public-private partnership driven by pharmaceutical companies in the field of autism. IMI launched in 2008 as a joint undertaking between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI's goal is to speed up the development of, and patient access to, safer and more effective medicines in fields as diverse as diabetes, medicines safety, clinical trial design, and the assessment of real-life effectiveness of new treatments. With a total budget of over EUR five billion for the period 2008-2024, IMI is the world's biggest public-private partnership in health; it forges collaborations between researchers in industry, academia, smalland medium-sized enterprises, patient groups, regulators, and others involved in health research and healthcare. In most cases, IMI projects are inspired and driven by industry. IMI enables the ''open innovation'' approach by acting as a neutral third party, providing impartial advice and guidance and ensuring that the interests of all project partners are respected when it comes to issues such as governance and intellectual property.
EU-AIMS was launched in 2012 (Murphy and Spooren, 2012) and has been one of the most successful of the 50 IMI projects launched to date, both in terms of scientific output and interactions between the different stakeholders including the European Medicines Agency (EMA), FDA, and patient advocates. For instance, Autism Speaks, the world's leading autism science and advocacy organization, supports EU-AIMS both scientifically and financially in developing large-scale biobanks and data repositories.
EU-AIMS brings together overlapping themes to underpin new drug discovery for ASDs. This reflects our belief that neither ''top-down'' clinical and translational studies, nor ''bottom-up'' model system analysis, can impact on ASDs alone. Rather, we need to integrate proven technologies around (for example) animal models and PET, together with new approaches (e.g., fMRI, and multiomics to identify candidate biomarkers, and induced pluripotent stem cells for drug screening). These integrated approaches are also applied to targets for clinical populations that encompass atrisk infants, children and adults with ASDs, and nonautistic individuals with genetic abnormalities that may be informative (e.g., those with synaptic gene defects). Our strategy, therefore, employs synergistic experimental work packages (WPs) bringing together animal model and patient studies to progress new translational approaches to ASDs. Together, the aim of these WPs is to deliver new validated assays, both in vivo and in vitro, that aid our understanding of etiology and deliver tractable platforms for drug discovery in ASDs (Figure 1 ).
To date, we have linked cellular deficits to systems-level abnormalities and ASDrelevant behavior by creating a centralized repository of rodent models with high construct and face validity that are shared by all partners. For instance, we recently showed that Nlgn3 knockout mice (a model for ASDs) display a convergent pathophysiology with fragile X syndrome, which could be genetically (Baudouin et al., 2012) and pharmacologically rescued. To translate findings from animals to humans (and back) we have already developed new translational neuroimaging stratification techniques , PET ligands, rodent touchscreen tests, and behavioral assays. For example, we reported structural and functional candidate biomarkers that are specific to ASDs (i.e., not found in other neurodevelopmental disorders such as ADHD) or that vary between males and females with ASDs (Lai et al., 2013) . Also, our proof-of-concept studies showed abnormalities in striatal glutamate concentration in both rodent models and adults with ASDs that are linked with abnormal functional connectivity and symptom severity (Horder et al., 2013) . Further, we reported that some brain functional anomalies can be reversed in ASDs (and even in adults) by targeting serotonin (Daly et al., 2012 (Daly et al., , 2014 . In parallel, we identified several new risk factors-e.g., we showed that father's age significantly increases the risk for ASDs (and schizophrenia) by increasing the rate of de novo copy-number variants (Kong et al., 2012) . However, developing new treatments also requires a clinical research and training platform to underpin clinical trials. Hence, we have created a unique clinical research platform comprising two large-scale multidisciplinary cohorts spanning (i) infants at risk for ASDs (''Eurosibs'') to identify early predictive markers for ASDs (before behavioral symptoms manifest), and (ii) children, adolescents, and adults with ASDs (''EU-AIMS LEAP'') to identify biomarkers that can be used to stratify patients into more homogeneous groups. To facilitate future drug trials in Europe, we have worked with patient organizations representing people with ASDs (e.g., Autism Europe and COST-ESSEA) to establish a new clinical trials network that currently includes 78 expert sites across 37 European countries. Future clinical trials, in turn, will require objective outcome markers that are accepted by the relevant regulatory authorities. Thus, EU-AIMS has led the way by being the first publicly funded research network to work with a regulatory authority, the EMA, to obtain qualification advice on how our experiments should be structured, so that any new treatment targets, stratification tools, or outcome markers we develop have a better chance of being accepted for use in clinical trials.
Hence, the EU is now at a stage that would have been unimaginable only a few years ago-we are on the cusp of being able to translate into man novel treatments for ASDs that target specific molecular deficits. To do this successfully, however, we need to learn from past mistakes and avoid reliance on subjective self-(or observer)-based reports and the use of brief and small-scale (i.e., underpowered) trials of heterogeneous populations that do not adapt to emerging data. Moreover, we will need to address the fact that the process for developing proof of concept is inefficient with companies launching similar products and targeting similar patient and control groups. This approach replicates effort, and lessons learnt from one failure (or success) are not shared. The future will therefore likely require studies of large numbers of extensively (''deep'') phenotyped individuals for a longer duration of time, using novel (e.g., adaptive) trial designs. For instance, adaptive clinical trials represent a more flexible and responsive approach for drug development in which researchers can simultaneously compare several candidate drugs to a placebo and test and compare drugs individually and in combination. As the effects of the candidate drugs are continuously measured and analyzed, researchers can adapt the trial in response to new findings. For example, if a candidate medicine appears to be particularly effective in specific categories of patients, then that medicine can be preferentially directed to those people to confirm this finding. Similarly, if a drug proves ineffective, it can be dropped from the trial, and new drugs can easily be added to it. This adaptive approach has already proven successful in breast cancer research and will soon be trialled via a new IMI project in the Alzheimer's field. Linked to adaptive trials, we suggest that more exploration is required of the concept of adaptive licensing, in which marketing approval for new medicines is granted in a staggered approach, starting with a (clearly identified) group for whom the need for a new treatment is the most urgent. As further evidence is gathered on the risks and benefits of the medicine, the approval may be extended to include further groups. Such an approach would be very much appropriate in ASDs, starting with homogeneous groups identified on the basis of genetic markers.
These new approaches have been adopted into the overall strategy defined for the next phase of the IMI (IMI 2). This second phase of IMI, which has just been launched, is focusing on innovative methods and tools ensuring rapid access of patients to innovative drugs. We anticipate that the efforts successfully pioneered by the EU-AIMS consortium will be pursued under IMI 2, including links to other international consortia and regulatory authorities outside Europe. Neuron and academic lead of EU-AIMS-one of the largest autism research programs in the world. Michel Goldman is a professor of immunology at the Université libre de Bruxelles. As the Executive Director of the Innovative Medicines Initiative, the largest public-private partnership in life sciences, he was responsible for the launch of the EU-AIMS consortium. Eva Loth is the Science Coordinator of the EU-AIMS project, and was instrumental in designing the EU-AIMS Longitudinal European Autism Project (LEAP) described in this piece. Will Spooren heads the Behavioral Pharmacology and Pre-clinical Imaging section at Hoffmann-La Roche Neuroscience. He is also a visiting professor at the Institute of Psychiatry at King's College London. He was instrumental in determining the strategy, focus, and setup of EU-AIMS and currently acts as its EFPIA coordinator. 
